c-Met Monoclonal Antibody (3D4) | Invitrogen 18-7366 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

c-Met Monoclonal Antibody (3D4)

catalog :

18-7366

quantity :

500 µL

price :

US 482

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

3D4

reactivity :

human, mouse

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, immunohistochemistry - paraffin section

more info or order :

Invitrogen product webpage

citations: 15

Published Application/Species/Sample/Dilution	Reference
western blot; human; 1:1000; loading ...; fig 4a	Martin V, Chiriaco C, Modica C, Acquadro A, Cortese M, Galimi F, et al. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours. Br J Cancer. 2019;120:527-536 pubmed publisher
immunohistochemistry - paraffin section; mouse; fig 5 western blot; mouse; fig 4	Morena D, Maestro N, Bersani F, Forni P, Lingua M, Foglizzo V, et al. Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes. elife. 2016;5: pubmed publisher
immunocytochemistry; human; tbl 2	Zhang T, Boominathan R, Foulk B, Rao C, Kemeny G, Strickler J, et al. Development of a Novel c-MET-Based CTC Detection Platform. Mol Cancer Res. 2016;14:539-47 pubmed publisher
ELISA; mouse western blot; mouse; fig s1	Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson A, et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature. 2015;522:349-53 pubmed publisher
immunohistochemistry - paraffin section; human; 1:200	Kim Y, Jin D, Lee B, Cho E, Han J, Shim Y, et al. RARÎ²2 hypermethylation is associated with poor recurrence-free survival in never-smokers with adenocarcinoma of the lung. Clin Epigenetics. 2015;7:32 pubmed publisher
western blot; human; fig 2	Mahadevan D, Theiss N, Morales C, Stejskal A, Cooke L, Zhu M, et al. Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST). Oncotarget. 2015;6:1954-66 pubmed
immunocytochemistry; human; 1:100	Xie Y, Lu W, Liu S, Yang Q, Carver B, Li E, et al. Crosstalk between nuclear MET and SOX9/?-catenin correlates with castration-resistant prostate cancer. Mol Endocrinol. 2014;28:1629-39 pubmed publisher
immunohistochemistry - paraffin section; human; 4 ug/ml; fig 3	Straussman R, Morikawa T, Shee K, Barzily Rokni M, Qian Z, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487:500-4 pubmed publisher
immunohistochemistry; human; 1:100; fig 3	Tretiakova M, Salama A, Karrison T, Ferguson M, Husain A, Vokes E, et al. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011;30:341-54 pubmed
western blot; human; fig 3	Seiwert T, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69:3021-31 pubmed publisher
immunohistochemistry - paraffin section; human; 1:50; loading ...; fig 2a	Kong D, Song S, Kim D, Joo K, Yoo J, Koh J, et al. Prognostic significance of c-Met expression in glioblastomas. Cancer. 2009;115:140-8 pubmed publisher
	Munoz R, Hileeto D, Cruz Munoz W, Wood G, Xu P, Man S, et al. Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. PLoS ONE. 2019;14:e0222580 pubmed publisher
	Schmitz K, Koeppen H, Binot E, Fassunke J, KÃ¼nstlinger H, Ihle M, et al. MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas. PLoS ONE. 2015;10:e0120079 pubmed publisher
	Marchion D, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles X, et al. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013;29:2011-8 pubmed publisher
	Tuynman J, Lagarde S, ten Kate F, Richel D, van Lanschot J. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer. 2008;98:1102-8 pubmed publisher

product information

Product Type :

Antibody

Product Name :

c-Met Monoclonal Antibody (3D4)

Catalog # :

18-7366

Quantity :

500 µL

Price :

US 482

Clonality :

Monoclonal

Purity :

purified

Host :

Mouse

Reactivity :

Human

Applications :

Immunocytochemistry: 1:250, Immunohistochemistry (Paraffin): Assay-dependent

Species :

Human

Clone :

3D4

Isotype :

IgG2a

Storage :

4° C

Description :

MET is a tyrosine kinase receptor for the hepatocyte growth factor. It is linked to functions such as cell proliferation, scattering, morphogenesis, and survival. Ligand binding at the cell surface induces autophosphorylation of MET that provides docking sites for downstream signaling molecules. After activation of the ligand, MET interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, and STAT3. There interactions lead to the activation of signaling cascades including RAS-ERK, PI3, kinase-AKT, and PLCgamma-PKC. MET plays a role in embryonic development including gastrulation, development of muscles and neurons, angiogenesis, and kidney formation. It also plays a role in adults including wound healing, organ regeneration, and tissue remodeling. MET has been linked to cancers including gastric, renal, and breast; therefore, making it a target for cancer therapeutics and diagnostic testing.

Immunogen :

Synthetic peptide derived from cytoplasmic domain of human c-Met protein.

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 1:250, Immunohistochemistry (Paraffin): Assay-dependent

Aliases :

AI838057; AUTS9; bHLHe59; CG1705; CG1705-PA; CG1705-PB; cmet; c-met; c-met proto-oncogene; c-Met receptor tyrosine kinase; c-Met/HGF receptor; D249; DFNB97; Dmel CG1705; Dmel_CG1705; DmMet; EC 2.7.10.1; Hepatocyte growth factor receptor; HGF; HGF receptor; HGF receptor c-Met; HGF/SF receptor; HGFR; HGF-SF receptor; juvenile hormone resistance; met; met proto-oncogene; met proto-oncogene (hepatocyte growth factor receptor); met proto-oncogene tyrosine kinase; MET proto-oncogene, receptor tyrosine kinase; Met/Met1; Met; protein tyrosin kinase; methoprene tolerant; Methoprene-tolerant; Methoprene-tolerant protein; Met-PA; Met-PB; Mett; oncogene MET; Par4; Proto-oncogene c-Met; RCCP2; resistance (1) juvenile H; resistance to juvenile hormone; Rst(1)JH; sc MET; scatter factor receptor; SF receptor; soluble c met; tyrosine-protein kinase Met

more info or order :

Invitrogen product webpage